Medicaid Monitor
Policy Intelligence
Medicaid Monitor
Policy Intelligence
Updated Fri 12:06 PM MT
© 2026 Lanphier Ventures, LLC
Informational use only. Not legal or compliance advice.
Source
← All Sources

STAT News

82 stories

Federal Policy·3d ago

CMS Finalizes Scaled-Back Medicare Drug Pricing Pilot

The Trump administration finalized the GLOBE rule, a mandatory pilot aimed at lowering Medicare prices for physician-administered drugs by benchmarking them to prices in other wealthy countries. The final version applies to only four drug companies, a steep reduction from the scope of the initial proposal, and excludes companies that already struck voluntary most-favored-nation pricing deals covering Medicaid drugs. A related mandatory pilot, GUARD, remains at the proposed-rule stage. The narrowed scope significantly limits projected savings compared to the original proposal.

Federal Policy·4d ago

States Face Deadline to Join Medicaid International Drug Pricing Pilot

In its D.C. Diagnosis newsletter, STAT reports that Wednesday is the deadline for states to opt into GENEROUS, a pilot program letting Medicaid access drugs at prices available abroad. Separately, the Senate health committee will vote Wednesday on three HHS nominees, but not on Heidi Overton, the nominee to lead the FDA, whose confirmation now won't be decided until after the Senate returns Nov. 9. CMS Administrator Mehmet Oz is also traveling to Texas to promote CHOICE arrangements, which let employers give workers tax-free funds to buy ACA Marketplace coverage.

Federal Policy·5d ago

CMS Ends Automatic Medicare Add-On Payments for Breakthrough Devices

CMS has finalized removal of the pathway that let FDA "breakthrough"-designated devices automatically qualify for supplemental Medicare payments, including new technology add-on payments and transitional pass-through payments, without demonstrating substantial clinical improvement or novelty. Device manufacturers are affected most directly, since new breakthrough-designated products will need to meet standard evidentiary requirements to secure extra payment starting in October. The change follows an August CMS rule finalizing the policy shift. While this is a Medicare payment policy change, Medicaid stakeholders should track it because device coverage and payment precedents set in Medicare often influence state Medicaid fee schedules and managed care benefit design for the same technologies.

Industry·5d ago

STAT Previews Midterm Election Stakes for Drug Pricing, Medicaid Policy

In its STAT+ preview, STAT reports that the outcome of the upcoming midterm elections could drive significant shifts in health care policy, including drug pricing rules, Medicaid funding, and research funding levels. The piece frames these as issues affecting hospitals, pharmaceutical companies, and by extension the state Medicaid programs and providers that depend on federal funding decisions. No specific legislative or regulatory action has occurred yet; the article previews potential outcomes tied to the midterm election results. Medicaid stakeholders should watch how election results could reshape federal funding and drug pricing policy in the coming budget and legislative cycles.

Federal Policy·9d ago

Trump Administration Claims All States Accepted GENEROUS Drug Pricing Model, Several States Deny Enrollment Decision

Trump administration officials announced that all states have agreed to participate in the GENEROUS model, a federal initiative designed to provide lower drug prices to state Medicaid programs. However, officials in multiple states say they have not committed to participation and are still evaluating whether GENEROUS offers better value than existing manufacturer rebate arrangements. Pricing details for the GENEROUS model remain unavailable to the public. The discrepancy raises questions about enrollment claims and creates uncertainty for state Medicaid agencies making coverage and financial planning decisions.

Federal Policy·11d ago

White House Drug Affordability Plan May Exclude Key Medications from Medicaid Cost Controls

The Trump administration has released a plan intended to reduce drug costs for Medicaid beneficiaries, but the policy contains an exception that may exempt certain medications from cost controls. The exception could allow manufacturers to avoid pricing restrictions that would otherwise apply to Medicaid drugs. The policy's structure may create differential treatment across drug classes, with potential financial implications for state Medicaid programs and health plans managing pharmacy benefits. Details on implementation timeline and which specific medications qualify for the exception remain to be clarified.

Federal Policy·12d ago

GOP Health Policy Expert Defends $1 Trillion Medicaid Cut Proposal

An influential Republican health policy expert is defending proposed $1 trillion cuts to Medicaid spending and identifying additional policy targets for future action. The article does not specify which Republican expert or what legislative vehicle would implement these cuts. The timing and likelihood of enactment are unclear given the need for congressional approval. For state Medicaid agencies and managed care organizations, these proposals signal continued federal-level debate over Medicaid financing that could affect coverage levels, eligibility, and capitation payments if enacted.

Federal Policy·13d ago

Trump Administration Launches Drug Pricing Initiative for State Medicaid Programs

The Trump administration announced a new federal initiative to offer discounted pharmaceuticals to state Medicaid programs, with reported participation from all states. The program, referred to as GENEROUS, aims to reduce prescription drug costs for Medicaid enrollees. Key operational details including pricing mechanisms, implementation timelines, and specific drug categories covered remain undisclosed. The initiative represents a federal effort to lower pharmaceutical spending in Medicaid, though states and managed care organizations await guidance on program structure and participation requirements.

Industry·16d ago

FDA Faces Staff Shortage That Hampers Agency's Ability to Expand Workforce

The Food and Drug Administration is experiencing a hiring bottleneck due to insufficient staffing resources to recruit and onboard new employees. This operational constraint affects the agency's ability to scale up its workforce even when funding and positions are authorized. The staffing limitation comes as FDA faces increasing regulatory responsibilities across drug approvals, medical device oversight, and food safety. While not directly a Medicaid story, this affects the broader regulatory environment in which Medicaid operates, particularly for drug approvals and medical device reviews that impact Medicaid coverage and spending decisions.

Federal Policy·20d ago

GOP Rural Health Fund Falls Short of Hospitals' Needs Amid Medicaid Cuts

Republican lawmakers created a $50 billion Rural Health Transformation Fund to offset the impact of proposed $1 trillion Medicaid cuts over ten years, but hospital leaders say the fund's structure and eligibility requirements fall short of addressing their needs. The fund was designed to cushion rural hospitals facing revenue losses from Medicaid reductions. Hospital executives report that the fine print limits which facilities qualify and how funds can be used, leaving many rural providers vulnerable to closures as Medicaid cuts take effect. The shortfall matters because rural hospitals depend heavily on Medicaid revenue and have limited alternative payer sources.

Federal Policy·22d ago

CMS Allows Tiered Medical Frailty Determinations for Medicaid Work Requirement Exemptions

CMS has issued new rules permitting states to use tiered systems when determining medical frailty exemptions from Medicaid work requirements. The guidance affects states with approved work requirement waivers and changes how beneficiaries qualify for exemptions based on health status. The rules take effect immediately for states implementing or operating work programs. Patient advocates warn the tiered approach could create administrative barriers that result in coverage loss for medically complex beneficiaries who struggle to navigate multi-level documentation requirements.

Industry·23d ago

Novartis Investor Calls for Board Shake-Up After Trial Failures Tank Shares

Artisan Partners, a major Novartis shareholder, is demanding board changes and improved acquisition oversight after the drugmaker's shares fell to record lows following two late-stage trial failures. The setbacks include a failed muscle-wasting disorder drug from Novartis's $12 billion Avidity acquisition and disappointing heart drug pelacarsen results. The investor criticized successive chairmen for poor deal oversight. Separately, CMS Administrator Mehmet Oz says the Trump administration is pursuing additional voluntary drug pricing deals with pharmaceutical companies beyond the two dozen agreements already announced.

Federal Policy·24d ago

Trump Administration Proposes AI Solutions Amid $1 Trillion Medicaid Rural Provider Cuts

The Trump administration is proposing artificial intelligence as a solution for rural health care providers facing nearly $1 trillion in Medicaid cuts over the next decade. Rural health leaders express skepticism about AI's ability to offset the financial impact of these proposed cuts. The cuts would affect hospitals, clinics, and other providers serving Medicaid beneficiaries in rural areas. The proposal reflects a broader federal strategy to reduce Medicaid spending while relying on technology to maintain access, though implementation details and timelines remain unclear.

Industry·26d ago

Rural Hospitals Accelerate M&A Activity Amid Anticipated Federal Medicaid Cuts

Rural hospital systems are pursuing mergers and partnerships in response to anticipated Medicaid funding reductions under the Trump administration. The consolidation wave is driven by financial survival concerns as rural facilities face revenue pressures from potential federal cuts. This activity is intensifying debate over healthcare market competition and care costs in rural communities. The timing and scope of any federal Medicaid reductions remain uncertain, but rural providers are acting preemptively to strengthen their financial positions through scale and integration.

Federal Policy·32d ago

House to Vote on Stopgap Bill Blocking White House Control Over Federal Research Grants

The House is expected to vote Tuesday evening on a Senate-passed stopgap funding bill that temporarily blocks a White House proposal to give political appointees control over federal research grants, including NIH funding. The bill will use a fast-track process requiring two-thirds support, indicating House GOP leadership expects passage. If the vote fails, lawmakers must wait until September 14 when the Senate returns to reconcile differences between the chambers. The proposal affects federal research funding that supports Medicaid-related health services research and demonstration projects.

Industry·32d ago

Novartis, Bristol Myers Pause Cell Therapy Trials After Three Patient Deaths

Novartis and Bristol Myers Squibb have halted multiple autoimmune cell therapy trials after inflammatory side effects emerged, including three patient deaths from immune reactions in Novartis trials of CAR-T candidate rap-cel. Bristol Myers voluntarily paused enrollment in autoimmune trials for its CAR-T treatment zola-cel. Both therapies use accelerated production technology compared to earlier CAR-T products. The pauses affect investigational treatments not yet approved for any indication, with unclear timelines for resumption.

Federal Policy·33d ago

Opinion Argues Trump Administration Increases Administrative Burden on Federal Health Programs

An opinion piece argues the Trump administration has increased administrative requirements for federal health programs, including Medicaid, and biomedical research grants. The authors claim these changes worsen the existing "time tax" — the 10.5 billion hours Americans spent on federal paperwork in 2023 — which the government estimates causes $140 billion in unclaimed benefits annually. The commentary suggests increased bureaucracy at HHS affects scientists seeking grants and Medicaid beneficiaries navigating enrollment or benefits. No specific policy changes or dates are detailed in the excerpt provided.

Industry·33d ago

Employers Reassess Health Benefits as GLP-1 Drug Costs Strain Budgets

Employers are fundamentally reconsidering health benefit design as spending on GLP-1 medications (Ozempic, Wegovy, Mounjaro) drives unprecedented cost increases. Self-insured employers and commercial health plans are implementing new coverage restrictions, prior authorization requirements, and cost-sharing structures to manage expenses that some benefit managers describe as unsustainable under current benefit designs. The shift is occurring across 2026 plan years as employers finalize benefits for 2027. This development matters primarily for commercial payers but has spillover implications for Medicaid programs in states that cover GLP-1s for weight loss, as commercial market strategies often preview Medicaid managed care utilization management approaches.

Federal Policy·34d ago

Trump Administration Announces Medicaid Drug Discount Agreements with Biotech Companies

The Trump administration plans to announce drug-pricing agreements with several midsized biotech companies on Monday, requiring the companies to provide discounts on outpatient drugs to state Medicaid programs aligned with foreign prices. Participation by state Medicaid programs is optional. In exchange, participating companies will be exempt from pilot programs forcing similar discounts in Medicare, and relief from tariffs is part of some discussions. The agreements represent a new federal approach to Medicaid drug pricing, though states retain discretion on participation.

Federal Policy·38d ago

Hospitals Launch Campaign Against $1 Trillion in Proposed Medicaid Cuts

Hospital associations are mobilizing opposition to proposed federal Medicaid cuts totaling $1 trillion, though prospects for reversal remain uncertain. The cuts would directly reduce payments to hospitals serving Medicaid beneficiaries, threatening provider networks and access to care. Healthcare systems are coordinating advocacy efforts targeting Congress and federal policymakers. The campaign reflects industry concerns about financial viability under reduced Medicaid reimbursement, particularly for safety-net hospitals with high Medicaid patient volumes.

Federal Policy·39d ago

Trump Administration Health Funding Cuts Prompt System-Wide Adjustments

The Trump administration has implemented health care funding cuts that are prompting adjustments across the health system, according to STAT reporting. The cuts affect multiple health programs and provider systems. The changes are currently being implemented. This matters for Medicaid stakeholders because federal funding reductions often lead to state budget pressures, potential cuts to optional services or populations, and increased scrutiny of managed care rates and administrative spending.

Managed Care·40d ago

Trump Administration Medicaid Obesity Drug Coverage Pledge Faces Implementation Hurdles

President Trump's commitment to expand Medicaid coverage for weight loss medications has not materialized in practice. The pledge aimed to make expensive obesity drugs accessible to low-income beneficiaries, but implementation has stalled. The development affects Medicaid agencies planning pharmacy benefits and managed care organizations managing pharmacy carve-ins. The gap between the announced policy intent and actual coverage expansion leaves states without federal guidance on obesity medication coverage requirements or financing mechanisms.

Legal·41d ago

Federal Court Ruling on Medicaid Transgender Care Could Restrict Other Drug Coverage

A federal court decision restricting Medicaid coverage of gender-affirming care for minors establishes legal precedent that could extend beyond transgender care, according to legal experts. The ruling's legal framework — which allows states to exclude specific treatments from Medicaid coverage based on medical necessity determinations — may be applied to restrict coverage of other drugs and services. State Medicaid agencies and managed care plans should monitor whether this precedent affects coverage requirements for treatments beyond gender-affirming care, particularly those subject to state-level medical necessity debates.

Industry·46d ago

Municipalities Cut Public Employee Health Benefits Amid Rising Insurance Costs

Municipalities across the United States are reducing health insurance benefits for government workers as costs continue to rise, according to a STAT report. Local governments are implementing higher deductibles, increased premium contributions, and narrower provider networks to manage budget pressures. The changes affect millions of public sector employees including teachers, police officers, and municipal staff. These benefit reductions reflect broader healthcare cost inflation impacting public sector budgets, though the specific impact on Medicaid programs or managed care operations is not detailed in the coverage.

State Policy·55d ago

Research Suggests Best Practices for State Medicaid Renewal Outreach Communications

Research examines effective methods for state Medicaid agencies to communicate with enrollees during renewal periods and help them navigate administrative requirements. The analysis addresses how states can improve outreach strategies to reach beneficiaries facing renewal deadlines and support completion of required paperwork. The findings aim to reduce procedural coverage losses during redetermination periods by improving communication effectiveness. States implementing renewal strategies or responding to federal reporting requirements may apply these evidence-based practices to improve retention rates.

State Policy·60d ago

States Move to Restrict Medicaid Coverage of ABA Therapy for Autism

Multiple states are implementing new restrictions on Applied Behavior Analysis (ABA) therapy coverage for children with autism under Medicaid. The changes include stricter prior authorization requirements, reduced therapy hour caps, and new medical necessity criteria. State Medicaid agencies cite rising program costs and utilization management concerns as drivers for the policy shifts. The restrictions affect access to the primary evidence-based treatment for autism covered by Medicaid, which serves as the largest payer of autism services nationally.

Federal Policy·61d ago

HHS Officials Dispute State Concerns Over Medicaid Coverage Loss Projections

HHS Secretary Robert F. Kennedy Jr. and CMS Administrator Mehmet Oz are characterizing concerns about Medicaid coverage losses as "myths," while state Medicaid directors report that recent federal policy changes are expected to result in significant disenrollment. The dispute centers on whether new eligibility verification requirements, work requirements, or other administrative changes constitute "cuts" when they reduce enrollment. State agencies are preparing for increased disenrollment based on federal guidance issued in recent weeks. The disagreement highlights tension between federal policymakers and state administrators responsible for implementing Medicaid changes.

Legal·65d ago

Federal Judge Denies States' Motion to Postpone Medicaid Work Requirements

A federal judge denied a motion from 26 states seeking to delay implementation of Medicaid work requirements announced by CMS in June. The ruling means the work requirements will proceed as scheduled, absent further legal action. The decision affects states that had challenged the timeline for implementing the requirements, which would condition Medicaid eligibility on meeting work or community engagement standards. The ruling has immediate implications for state Medicaid agencies preparing operational and system changes to comply with the federal policy.

Managed Care·76d ago

State Medicaid Audit Reveals PBM Tactics That Inflate Drug Costs

A state Medicaid audit uncovered tactics pharmacy benefit managers use to obscure prescription drug costs, resulting in overcharges to taxpayers. The audit identified complicated claims processing methods that increased Medicaid spending beyond what would be expected under transparent pricing. The findings affect states contracting with PBMs directly or through managed care organizations for pharmacy services. The disclosure raises questions about PBM oversight requirements and potential recoupment of overpayments.

Federal Policy·79d ago

CMS Proposes Payment Model Changes for Remote Patient Monitoring and Clinical AI

The Centers for Medicare and Medicaid Services has proposed significant changes to how it pays for remote patient monitoring (RPM) and clinical artificial intelligence tools. The proposal would restructure payment models for these technologies under Medicare. The changes affect how health plans and providers bill for AI-enabled clinical decision support and remote monitoring services. CMS has opened the proposal for public comment, with implementation timing to be determined following the comment period.

Federal Policy·80d ago

CMS Proposes Standardized Payment Structure for Clinical Software and AI Tools

The Centers for Medicare & Medicaid Services announced plans to develop a standardized payment framework for clinical software and artificial intelligence tools that incorporates patient outcome measures. The proposed structure would establish consistent reimbursement methodology across Medicare and Medicaid for digital health technologies currently paid through fragmented billing codes or bundled into other services. CMS has not specified an implementation timeline or comment period. For Medicaid managed care organizations, this signals potential changes to how digital therapeutics, clinical decision support tools, and AI-driven care management platforms are covered and reimbursed under capitated arrangements.

Legal·80d ago

Glenmark Settles State Price-Fixing Claims for $29.6 Million

Glenmark Pharmaceuticals agreed to pay $29.6 million to settle price-fixing allegations brought by multiple states. The settlement resolves a multi-year investigation into alleged anti-competitive conduct involving drug pricing. The agreement covers claims from dozens of states that alleged Glenmark engaged in collusion to fix prices on generic pharmaceuticals. This settlement follows a pattern of similar enforcement actions against generic drug manufacturers over the past several years.

Industry·80d ago

Elevance Health Plans Further Medicaid Portfolio Exit Amid High Costs

Elevance Health, the nation's second-largest health insurer, announced plans to reduce its Medicaid managed care footprint over the next year as medical costs remain elevated. The exit comes as states prepare to implement Medicaid work requirements. Elevance operates Medicaid plans in multiple states under its Anthem and Wellpoint brands. The decision reflects ongoing profitability challenges in Medicaid managed care following the end of pandemic-era continuous enrollment provisions.

Industry·81d ago

FTC Settles with CVS Caremark Over Insulin Price Manipulation Claims

The Federal Trade Commission has settled a lawsuit against CVS Caremark over allegations the company artificially inflated insulin prices and restricted access to diabetes treatment. The settlement resolves FTC charges related to the pharmacy benefit manager's pricing practices for insulin products. The action follows broader federal scrutiny of PBM practices affecting drug pricing and access. Terms of the settlement were not disclosed in the initial report.

Industry·81d ago

HHS Secretary Kennedy Advances Initiative to Reduce SSRI Antidepressant Use

U.S. Health and Human Services Secretary Robert F. Kennedy Jr. is moving forward with an initiative aimed at helping Americans discontinue selective serotonin reuptake inhibitor (SSRI) antidepressants. The effort represents a significant policy shift at the federal level regarding mental health treatment approaches. The initiative's specific implementation mechanisms, timeline, and scope remain unclear from available reporting. For Medicaid managed care organizations, any federal guidance or directives affecting prescription psychiatric medications could have major implications for behavioral health benefit design, formulary management, prior authorization protocols, and member continuity of care.

Federal Policy·81d ago

Home Care Workers Face Pay Cuts as Medicaid Reimbursement Rates Fall

Home care workers providing services to Medicaid beneficiaries are facing potential pay reductions that could affect workforce stability in the home and community-based services sector. The pay cuts stem from changes in Medicaid reimbursement rates, threatening the financial security of direct care workers who provide essential LTSS services. The workforce disruption could affect continuity of care for Medicaid managed care enrollees who rely on home care services. For MCOs with LTSS contracts, caregiver turnover and recruitment challenges may increase as workers leave the sector.

Industry·81d ago

HCA Reports Lower Profits as Uninsured Patient Volume Rises After ACA Subsidy Expiration

Hospital chain HCA Healthcare reported declining profits attributed to increased uninsured patient volume following the expiration of enhanced Affordable Care Act subsidies. The company cited rising uncompensated care costs as patients lost marketplace coverage. This represents an early signal of coverage losses affecting provider revenues after the federal government allowed pandemic-era ACA premium subsidies to lapse. The trend may accelerate Medicaid enrollment as individuals lose private coverage and income-qualify for state programs.

Industry·82d ago

AIDS Activists Obtain Biden-Gilead HIV Prevention Patent Settlement R&D Agreement

AIDS activists have obtained a research and development agreement that formed the basis of a settlement between the Biden administration and Gilead Sciences concerning patents for HIV prevention drugs. The activists are criticizing the terms of the settlement deal. The agreement relates to pre-exposure prophylaxis (PrEP) medications used to prevent HIV transmission. This development follows years of dispute over whether the federal government held patent rights to Gilead's HIV prevention drugs and the terms under which those drugs should be made available.

Federal Policy·83d ago

HHS Develops Guidance to Reduce SSRI Antidepressant Prescribing

The Department of Health and Human Services is working with mental health professionals to develop guidance aimed at reducing the use of selective serotonin reuptake inhibitor (SSRI) antidepressants. HHS officials convened a private meeting to advance this effort. The timing and scope of any formal guidance release remain unclear. For Medicaid managed care organizations, this could signal future prior authorization requirements, utilization management changes, or quality measure adjustments affecting behavioral health pharmacy benefits and member care protocols.

State Policy·83d ago

States Consider Wage Cuts for Family Caregivers of People with Disabilities

Multiple states are considering significant wage reductions for family caregivers who provide care to people with disabilities through Medicaid programs. These proposed cuts respond to state budget pressures following recent Medicaid funding reductions. The wage cuts would directly affect family members who serve as paid caregivers under state long-term services and supports programs. The changes threaten the financial stability of thousands of family caregivers who depend on these wages while providing essential home and community-based services.

Industry·87d ago

Trump Officials Press Drug Industry to Onshore Generic Manufacturing

Secretary of State Marco Rubio, HHS Secretary Robert F. Kennedy Jr., and CMS Administrator Chris Klomp held a private meeting with pharmaceutical industry leaders to encourage domestic production of generic drugs. The officials are pushing companies to shift manufacturing capacity from overseas facilities, particularly from China and India, back to the United States. The timing and specific policy mechanisms for incentivizing onshoring were not detailed in the reporting. The initiative reflects ongoing federal concerns about pharmaceutical supply chain vulnerabilities that have periodically disrupted access to essential medications, including those covered by Medicaid managed care plans.

Industry·88d ago

FDA Approves Over-the-Counter CGM for Childhood Obesity Management

The FDA has approved an over-the-counter continuous glucose monitor (CGM) for use in young children, including toddlers as young as two years old, as a tool for childhood obesity management. The approval represents a significant shift in glucose monitoring technology from prescription diabetes management to preventive wellness applications in the pediatric population. Medical experts are evaluating the clinical benefits of real-time glucose data for obesity prevention against potential risks including device-related anxiety, misinterpretation of normal glucose fluctuations in non-diabetic children, and the appropriateness of medical device use in very young children. The approval takes effect immediately with retail availability expected in the coming months.

Legal·CO·93d ago

Federal Judge Blocks Colorado Drug Affordability Board Price Cap on Amgen's Enbrel

A federal judge has blocked Colorado's Drug Affordability Board from implementing a price cap on Amgen's Enbrel, a blockbuster rheumatoid arthritis medication. The ruling prevents the state board from enforcing its pricing limit on the drug. The decision affects Colorado's ability to use its drug affordability review process to control costs for high-priced medications. This represents a significant setback for state efforts to directly regulate pharmaceutical pricing through affordability boards, with implications for how states can address drug costs in Medicaid programs.

Federal Policy·96d ago

Trump Administration Obesity Drug Agreement Faces Implementation Issues

The Trump administration's negotiated agreement with Eli Lilly and Novo Nordisk regarding obesity medication pricing and coverage is encountering implementation problems. The deal, which was intended to expand access to GLP-1 medications while controlling costs, contains unspecified loopholes or structural issues affecting its execution. The problems impact how these high-cost medications are covered and reimbursed under federal health programs. Medicaid managed care organizations should monitor whether state programs adjust coverage policies or capitation rates in response to these federal-level complications.

Legal·TX·96d ago

AstraZeneca Pays $34 Million to Settle Texas Medicaid Kickback Claims

AstraZeneca agreed to pay $34 million to resolve allegations brought by the Texas Attorney General that the company paid kickbacks to improperly influence prescriptions reimbursed by Texas Medicaid. The settlement resolves claims that the pharmaceutical manufacturer violated anti-kickback statutes through payments that influenced prescribing behavior for drugs covered under the state's Medicaid program. The settlement does not include an admission of liability but ends the state's enforcement action against the company.

Federal Policy·96d ago

Senators Pursue $35 Insulin Cap for Private Insurance and Uninsured

U.S. senators are advancing legislation to extend the $35 insulin cost cap beyond Medicare to cover private insurance and uninsured individuals. The Medicare cap, enacted under the Inflation Reduction Act, currently applies only to Medicare Part D beneficiaries. The proposed expansion would affect Medicaid managed care organizations that coordinate care for dual-eligible beneficiaries and states with Medicaid pharmacy carve-ins where commercial insulin pricing dynamics affect beneficiary access. No effective date or legislative timeline is specified in the report.

Managed Care·96d ago

988 Suicide Hotline Expands LGBTQ-Specific Services

The 988 Suicide and Crisis Lifeline is expanding specialized services for LGBTQ+ populations. The expansion addresses higher rates of crisis calls and mental health needs among LGBTQ+ individuals, particularly youth. For Medicaid managed care organizations, this development affects crisis service coordination and behavioral health network adequacy requirements, as many states require MCOs to integrate 988 into their crisis response systems. MCOs should assess whether their behavioral health networks can support LGBTQ-competent follow-up care for individuals diverted from emergency departments through 988.

Industry·99d ago

Proposed Legislation Would Restructure Federal 340B Drug Pricing Program

Congressional legislation has been introduced to overhaul the 340B drug discount program, which requires pharmaceutical manufacturers to provide discounted outpatient drugs to eligible healthcare providers. The bill would restructure eligibility requirements and oversight mechanisms for the program that currently serves safety-net providers including some Medicaid managed care organizations and federally qualified health centers. If enacted, the changes would affect how covered entities access discounted medications and could alter prescription drug cost structures for Medicaid plans contracting with 340B-eligible providers. The proposal comes amid ongoing disputes between manufacturers and covered entities over contract pharmacy arrangements and duplicate discount prohibitions.

Industry·100d ago

Jails Face Medetomidine-Laced Opioid Withdrawal Crisis Without Treatment Protocols

Correctional facilities are increasingly encountering severe withdrawal cases from opioids contaminated with medetomidine, a veterinary sedative, but lack established treatment protocols for this emerging threat. The drug causes life-threatening withdrawal symptoms distinct from traditional opioid withdrawal, including extreme cardiovascular instability. Jails serve as unintentional frontline medical facilities as individuals enter custody experiencing these dangerous withdrawal episodes. Many facilities remain unprepared with limited access to specialized medical staff or evidence-based treatment approaches for this substance combination.

Federal Policy·100d ago

Cassidy Introduces Bill to Limit Hospital 340B Drug Discount Eligibility

Senator Bill Cassidy has introduced legislation to restrict eligibility for the 340B drug discount program, which allows certain hospitals and health centers to purchase outpatient drugs at steep discounts. The proposal comes as hospitals face broader federal funding pressures. While specific provisions are not detailed in the brief article, any 340B restrictions typically target hospital eligibility criteria, contract pharmacy arrangements, or program oversight. The timing is significant as hospitals already navigate budget constraints and prior 340B enforcement actions.

Federal Policy·101d ago

Bipartisan Bill Would Allow Direct Methadone Prescribing for Opioid Use Disorder

A bipartisan bill in Congress would end the requirement that methadone for opioid use disorder be dispensed only through specialty opioid treatment programs, allowing qualified practitioners to prescribe it directly like buprenorphine. The legislation would enable office-based prescribing and pharmacy dispensing of methadone, dramatically expanding access beyond the current clinic-only model. If enacted, the change would remove a longstanding barrier to medication-assisted treatment that has limited access particularly in rural and underserved areas. The timing and specific requirements for prescriber qualifications remain unclear pending legislative details.

Federal Policy·103d ago

Supreme Court Could Review Executive Order Ending Birthright Citizenship

An opinion piece argues that if the Supreme Court upholds a recent executive order ending birthright citizenship, the policy could create significant public health consequences. The analysis suggests potential impacts on healthcare access and population health outcomes. The piece frames the issue through bioethics and public health lenses. No specific timeline for Supreme Court review is provided in the available content.

Federal Policy·104d ago

White House Proposal Threatens Federal Funding for Health Equity Research

A new White House proposal could disqualify significant portions of health disparities research from federal funding eligibility. Health equity researchers characterize this as potentially the most serious threat to their field's future. The proposal would subject health equity studies to heightened scrutiny in federal grant review processes. The change would affect how agencies like NIH and AHRQ evaluate research focused on racial, ethnic, and socioeconomic health disparities.

Managed Care·106d ago

Half of U.S. Counties Lack OB-GYN Despite Declining Birth Rates

Nearly half of U.S. counties have no practicing obstetrician or gynecologist, creating maternity care deserts despite declining fertility rates. The shortage stems from systemic workforce and reimbursement issues rather than demand pressures. Many rural and underserved areas lack adequate prenatal and delivery services, forcing pregnant beneficiaries to travel long distances for care. The gap affects Medicaid managed care organizations' ability to meet network adequacy standards and HEDIS measures for prenatal and postpartum care.

Federal Policy·107d ago

Federal Grant Delays Threaten Disability Research Institutions and Services

Federal agencies have delayed issuing grants to disability research institutions nationwide, creating uncertainty about program continuity and employment. The delays affect research centers that study and support services for people with disabilities, including those enrolled in Medicaid long-term services and supports. No timeline has been provided for when grant awards will resume. The disruption threatens institutional stability and could interrupt data collection and technical assistance that state Medicaid programs rely on for LTSS policy development.

Federal Policy·108d ago

CDC Reports 1,415% Increase in Nitazene Overdose Deaths Since 2020

The CDC reported nitazene-involved overdose deaths increased from 27 in 2020 to 409 in 2024, marking a 1,415% rise in confirmed fatalities from these super-potent synthetic opioids. Nitazenes are spreading across the U.S. drug supply, often mixed with or sold as other substances. The sharp escalation indicates an emerging public health threat requiring enhanced overdose response capacity. This trend follows patterns seen with fentanyl's emergence in the illicit drug market over the past decade.

Industry·108d ago

STATus Report Episode Examines GLP-1 Weight Loss Drug Pipeline

STAT News published a video episode examining the future trajectory of GLP-1 weight loss medications. The segment, hosted by Alex Hogan, explores upcoming developments in the GLP-1 drug class, which includes medications like Ozempic and Wegovy. The episode appears to focus on market trends and pharmaceutical industry developments related to these medications. No specific policy changes, regulatory actions, or Medicaid coverage decisions are reported.

Federal Policy·109d ago

Medicare Coverage of Anti-Obesity Drugs Begins Next Month Under Temporary Program

Medicare will begin covering weight loss medications starting next month through a program designed as temporary but expected to face political pressure for permanence. The coverage represents a significant policy shift for Medicare, which has historically excluded anti-obesity drugs from its formulary. The program's implementation comes as GLP-1 medications like Wegovy and Zepbound have demonstrated clinical efficacy for weight management but carry substantial cost implications. While positioned as temporary, the coverage expansion may prove difficult to reverse once beneficiaries begin accessing these medications.

Federal Policy·CO·110d ago

FDA Approves Colorado Drug Importation Plan from Canada

The FDA approved Colorado's Section 804 importation program, allowing the state to import certain prescription drugs from Canada to reduce costs for residents. This marks the first operational approval under the 2020 FDA guidance that permits states to seek authorization for Canadian drug importation. The approval comes after years of state planning and federal review. Colorado must now finalize vendor contracts and operational logistics before importing drugs, with implementation timeline still uncertain.

State Policy·111d ago

State Medicaid Fraud Crackdowns Reduce Provider Access for Disability Services

States are implementing stricter fraud enforcement measures in Medicaid programs serving people with disabilities, following federal directives. The increased scrutiny has led to provider exits from Medicaid networks, creating access challenges for beneficiaries requiring home and community-based services and other disability supports. States are balancing program integrity goals against network adequacy concerns as providers cite compliance burdens and payment delays. The enforcement trend affects multiple states and continues to evolve as federal Medicaid policy emphasizes fraud prevention.

Industry·111d ago

Drug Shortage Confusion Leads to Preventable Congenital Syphilis Case in Arizona

A newborn in Arizona was diagnosed with congenital syphilis after the mother could not access penicillin through Pfizer's emergency allocation program during a national drug shortage. The case illustrates how supply chain disruptions and access barriers to penicillin — the only FDA-approved treatment for syphilis in pregnancy — are contributing to rising congenital syphilis rates. The CDC reported over 3,700 congenital syphilis cases in 2022, up from 335 in 2012. Medicaid covers approximately 42% of all births nationally and a disproportionate share of pregnancies affected by syphilis, making prenatal screening and treatment access critical managed care quality measures.

Managed Care·114d ago

AMA and Lawmakers Target AI-Driven Prior Authorization Denials by Health Plans

The American Medical Association and members of Congress are pushing back against health insurers' use of artificial intelligence to deny prior authorization requests and coverage determinations. The scrutiny follows an HHS Office of Inspector General report documenting denial patterns by Medicare Advantage plans. Lawmakers are considering legislation to increase transparency and oversight of AI-driven utilization management tools. The controversy affects all payer types, including Medicaid managed care organizations that increasingly rely on automated systems for prior authorization and care management decisions.

Industry·115d ago

Average Drug Shortage Duration Reaches 5.3 Years in 2025

A new analysis shows the average drug shortage in 2025 has lasted 5.3 years, up from 4.3 years in 2024. The extended duration reflects chronic supply chain instability affecting generic medications, many of which are used extensively in Medicaid populations. The analysis highlights growing challenges in maintaining formulary stability and managing therapeutic alternatives. For Medicaid managed care plans, prolonged shortages complicate prior authorization processes, increase member access issues, and drive utilization of more expensive therapeutic substitutes.

Federal Policy·116d ago

Federal Actions Prompt Debate Over Methadone and Buprenorphine Access

Recent federal actions and proposals have sparked renewed debate over the use of methadone and buprenorphine for opioid use disorder treatment. Addiction medicine experts and patient advocacy organizations have expressed concern about potential restrictions on medication-assisted treatment (MAT). The developments come as Medicaid managed care organizations cover the majority of MAT services nationally, with medication costs and behavioral health integration representing significant budget and network adequacy considerations. Any federal policy changes affecting MAT access would directly impact MCO formularies, prior authorization protocols, and substance use disorder program design.

Industry·116d ago

U.S. Drug Shortages Fell 23% in 2024 Despite Ongoing Systemic Supply Issues

Prescription drug shortages in the United States decreased by 23% in 2024 according to a new analysis, but systemic supply chain problems persist. The analysis identified ongoing structural vulnerabilities in pharmaceutical manufacturing and distribution that continue to affect medication availability. While the overall number of shortages declined, the duration and severity of certain shortages worsened. For Medicaid managed care organizations, drug shortages create formulary management challenges, increase member access barriers, and complicate pharmacy benefit administration when preferred products become unavailable.

Managed Care·117d ago

UnitedHealthcare Changes Lactation Counseling Reimbursement Policy

UnitedHealthcare is revising its reimbursement methodology for lactation counseling services, a change that is expected to reduce payment rates for many providers. The policy modification affects how the nation's largest health insurer compensates lactation consultants and counselors who provide services to new mothers. The timing and specific payment methodology changes were not detailed in available reporting. The adjustment comes as maternal health services remain under scrutiny, particularly given federal emphasis on improving maternal health outcomes and access to postpartum care.

Industry·118d ago

Health Economist Calls for New Payment Infrastructure for Gene Therapies

Health economist William Padula argues that high-cost gene therapies, including treatments costing $2 million or more, require new financing models to enable patient access. The commentary asserts that the barrier to deploying curative therapies is not scientific but financial and infrastructural. Padula contends that existing payment systems are ill-equipped to handle the upfront costs of one-time curative treatments. The piece calls for innovative financing mechanisms to bridge the gap between therapeutic breakthroughs and patient access.

Industry·118d ago

ADA Conference Highlights Obesity Drug Competition and Clinical Practice Gaps

The American Diabetes Association's annual conference featured industry discussions on the competitive landscape for GLP-1 obesity medications and identified clinical blind spots in diabetes care delivery. The conference addressed how pharmaceutical competition is shaping market access and pricing dynamics for widely-used medications including semaglutide and tirzepatide. For Medicaid managed care organizations, these developments directly affect formulary strategy, prior authorization protocols, and budget forecasting for one of the fastest-growing drug spending categories.

Federal Policy·120d ago

Trump Administration Removes Civil Service Protections for Thousands of HHS Policy Staff

The Trump administration has reclassified thousands of HHS employees who shape policy to Schedule F status, stripping civil service protections and making them easier to terminate. The change affects staff across HHS agencies including CMS who develop regulations, guidance, and policy implementation. This action mirrors a similar executive order from Trump's first term that was rescinded by the Biden administration. The reclassification takes effect immediately and could lead to significant turnover among career staff who oversee Medicaid policy development and managed care oversight.

Federal Policy·122d ago

CMS Interprets Medicaid Cuts Law Without Cancer Patient Protections Advocates Expected

CMS has issued guidance interpreting recent Medicaid legislation in a manner that cancer patient advocates argue fails to deliver promised protections from coverage cuts. Blood Cancer United's Gwen Nichols warns that vulnerable oncology patients face exposure to benefit reductions or coverage limitations despite congressional assurances. The interpretation affects how states and managed care organizations implement Medicaid changes affecting cancer treatment access and continuity of care. The guidance creates immediate operational uncertainty for MCOs managing oncology benefits and prior authorization protocols.

Industry·122d ago

Providers and Insurers Deploy AI Tools for Prior Authorization and Claims Battles

Healthcare providers and insurers are increasingly using artificial intelligence to automate prior authorization requests and claims denials, creating an escalating technological arms race in medical billing. Providers use AI to generate documentation and appeals, while payers deploy AI to review and deny claims at scale. The automation may reduce administrative burden but also risks accelerating denials without human clinical judgment. This trend affects Medicaid managed care organizations that already face scrutiny over prior authorization delays and denial rates.

Federal Policy·123d ago

Lilly Threatens to End 340B Discounts for Hospitals That Don't Submit Claims Data

Eli Lilly issued a five-day ultimatum to hospitals participating in the 340B drug discount program, demanding they submit claims data or lose access to discounted pricing. The move escalates pharmaceutical manufacturers' ongoing efforts to restrict 340B eligibility and impose new compliance requirements on covered entities. Hospitals that fail to comply by the deadline will see their 340B discounts suspended. This follows similar manufacturer-led restrictions that have drawn pushback from HRSA and advocacy groups representing safety-net providers.

State Policy·123d ago

Medically Tailored Meal Programs Reduce Hospital Use in State Medicaid Population

A state Medicaid program demonstrated that medically tailored meal interventions reduced hospital utilization and healthcare costs among high-need beneficiaries. The program provided nutrition services targeting members with diet-sensitive chronic conditions. Results showed measurable decreases in inpatient admissions and emergency department visits among participating members compared to controls. The findings support growing interest in addressing social determinants of health through Medicaid managed care benefit design.

State Policy·123d ago

States Target Corporate Practice of Medicine in Telehealth Crackdown

Multiple states are introducing legislation to restrict corporate ownership structures that underpin most direct-to-consumer telehealth platforms. The legislative push focuses on corporate practice of medicine doctrine, which prohibits non-physician entities from employing physicians or controlling medical decisions. These state actions could force telehealth companies to restructure their business models or exit certain markets. The timing coincides with increased regulatory attention on telehealth prescribing practices following pandemic-era flexibilities.

Federal Policy·128d ago

Trump Administration Pharmaceutical Pricing Agreements Face Implementation Questions

The Trump administration's most favored nation (MFN) pricing agreements with pharmaceutical manufacturers remain under scrutiny as implementation details emerge. These agreements aim to tie U.S. drug prices to lower international reference prices. Medicaid managed care organizations may see indirect effects through pharmacy benefit design and supplemental rebate negotiations, though the agreements primarily target Medicare Part B and Part D. The timing and scope of implementation remain uncertain, creating planning challenges for health plans managing pharmacy benefits across multiple programs.

Industry·129d ago

CVS Restores Lilly Obesity Drug to Formularies After Prior Removal

CVS Health has returned Eli Lilly's obesity medication to its formularies after previously removing it. This formulary reinstatement affects Medicaid managed care organizations that contract with CVS Caremark for pharmacy benefit management services, potentially expanding access to GLP-1 medications for Medicaid enrollees. The decision reverses a prior coverage restriction and may influence pharmacy spending and prior authorization protocols. Managed care plans should review their pharmacy contracts and assess budget impact from potential increased utilization of high-cost obesity treatments.

Federal Policy·129d ago

FDA Relaxes Oversight of Blood Pressure Wearables, Raising Clinical Accuracy Concerns

The FDA has relaxed regulatory oversight of wellness wearable devices, allowing blood pressure monitoring technology to enter the market without clinical validation. This policy shift enables consumer devices with unverified accuracy to proliferate, potentially affecting remote patient monitoring programs that Medicaid managed care organizations use for hypertension management and chronic disease monitoring. MCOs relying on wearable data for care management and quality metrics should assess whether their contracted devices meet clinical accuracy standards, particularly for programs serving members with cardiovascular conditions.

Industry·129d ago

Trump Drug Pricing Deals Face First Test as New Launches Reveal List Prices

Seventeen pharmaceutical manufacturers that signed most-favored-nation pricing agreements with the Trump administration are beginning to launch new products, providing the first public test of whether these voluntary commitments will constrain launch prices. The agreements, which pledge U.S. list prices will not exceed prices in other developed nations, lack formal enforcement mechanisms and apply only to new products launched after signing. For Medicaid managed care organizations, these launches will reveal whether rebate strategies and supplemental rebate negotiations need adjustment, particularly if launch prices come in lower than historical benchmarks would predict.

Industry·129d ago

GSK hepatitis B drug achieves functional cure in 1 in 5 patients

An experimental GSK drug achieved functional cure in approximately 20% of chronic hepatitis B patients in new clinical trial data, significantly outperforming existing treatments. The results represent a potential breakthrough in treating chronic hepatitis B, which affects millions globally and can lead to liver cirrhosis and cancer. For Medicaid managed care organizations, improved hepatitis B treatments could reduce long-term pharmacy costs and downstream complications requiring expensive specialty care, particularly relevant given Medicaid's high enrollment of populations at elevated risk for chronic hepatitis B.

Industry·129d ago

Sen. Durbin Claims Trump Administration Enables Tobacco Marketing to Minors

Senator Dick Durbin criticizes the Trump administration for allegedly allowing tobacco companies to market nicotine products to children. The opinion piece focuses on regulatory enforcement gaps rather than specific policy changes affecting Medicaid programs. While youth nicotine addiction can lead to long-term health consequences that may increase Medicaid costs, this op-ed does not address managed care operations, coverage policies, or state program administration. The piece represents political commentary on federal tobacco regulation rather than actionable guidance for Medicaid plans.

Industry·129d ago

Stanford Pilots Patient Input Process for Clinical AI Tool Adoption

Stanford Health Care has implemented a patient engagement process to gather feedback before deploying new artificial intelligence tools in clinical settings. The health system is soliciting patient perspectives on proposed AI applications to identify concerns and implementation challenges before rollout. This approach represents an emerging practice in health system governance as AI tools become more prevalent in clinical workflows. For Medicaid managed care organizations, patient engagement protocols for AI adoption may become relevant as plans evaluate clinical decision support tools, prior authorization algorithms, and utilization management systems.

Industry·129d ago

FDA Extends Decision Deadline for AstraZeneca Breast Cancer Drug After Advisory Panel Opposition

The FDA has extended the decision deadline for AstraZeneca's experimental breast cancer pill following an advisory panel's negative vote on the drug's approval. The delay affects potential formulary decisions for Medicaid managed care organizations that cover cancer treatments. Medicaid MCOs should monitor the FDA's final decision timeline as it will impact prior authorization protocols and specialty pharmacy networks for oncology services. The extension creates uncertainty for health plans developing 2024 drug coverage policies.

Get the daily briefing.